

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

grant a product specific waiver

MHRA-101846-PIP01-25

Scope of the Application

Active Substance(s)

budigalimab

Condition(s)

Treatment of all conditions inc. in the category of malignant neoplasms except melanoma, CNS neoplasms, haematopoietic and lymphoid tissues neoplasms

Pharmaceutical Form(s)

Powder for solution for infusion, Solution for infusion

Route(s) of Administration

INTRAVENOUS USE

Name / Corporate name of the PIP applicant

AbbVie Ltd

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, AbbVie Ltd submitted to the licensing authority on 15/12/2025 15:03 GMT an application for a Waiver

The procedure started on 23/12/2025 12:22 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101846-PIP01-25

Of 07/01/2026 18:29 GMT

On the adopted decision for budigalimab (MHRA-101846-PIP01-25) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan).

This decision applies to a Waiver for budigalimab, Powder for solution for infusion, Solution for infusion , INTRAVENOUS USE .

This decision is addressed to AbbVie Ltd, AbbVie House, Vanwall Road, Maidenhead, UNITED KINGDOM, SL6 4UB

ANNEX I

1. Waiver

1.1 Condition:

Treatment of all conditions included in the category of malignant neoplasms except melanoma, central nervous system neoplasms, haematopoietic and lymphoid tissues neoplasms The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 18 years of age. Pharmaceutical form(s): Powder for solution for infusion Solution for infusion Route(s) of administration: INTRAVENOUS USE Reason for granting waiver: on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan:

2.1 Condition(s):

Not Applicable.

2.2 Indication(s) targeted by the PIP:

Not Applicable.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Not Applicable.

2.4 Pharmaceutical Form(s):

Not Applicable.

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures		
Non-Clinical Studies		
Clinical Studies		
Extrapolation, Modeling & Simulation Studies		
Other Studies		
Other Measures		

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	
Date of completion of the paediatric investigation plan:	
Deferral of one or more studies contained in the paediatric investigation plan:	

